Vaccine suitable for multi-species lipid-lowering blood-sugar-lowering castration, and preparation method and application thereof
By designing a vaccine against FSHβ subunit, using rigid linkers and TEV enzyme cleavage sequences to form a stable antigen structure, various metabolic problems caused by increased FSH were solved, and significant lipid and blood sugar lowering effects were achieved, and animals were provided. Application value of sterilization.
Patent Information
- Application Number
- CN202410927341.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-11
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2044-07-11
AI Technical Summary
The existing technology is difficult to effectively solve problems such as obesity, osteoporosis, atherosclerosis, hypercholesterolemia and neurodegenerative diseases caused by elevated FSH, especially in menopause women and animals that need sterilization, which lacks effective Immune castration method.
A multi-species vaccine is designed to lower lipids and blood sugar. It targets specific fragments of the FSHβ subunit, and is linked through a rigid linker and TEV enzyme cleavage sequence to form a stable dimeric antigen structure, and fuses antimicrobial peptides at the C-terminus of the antigen to form a Enhance immunogenicity and is suitable for topical or systemic administration.
The vaccine can significantly reduce intraluminal fat, triglycerides, blood sugar and total cholesterol levels, and has the effect of sterilizing pets and animals, showing potential effects in the treatment of obesity, hyperlipidemia, hyperglycemia and other diseases caused by ovarian dysfunction.
Smart Images

Figure CN118873643A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of vaccine technology, and in particular to a vaccine suitable for reducing lipids, blood sugar and castration in multiple species, a preparation method and application thereof. Background Art
[0002] Follicle-stimulating hormone (FSH) is a glycoprotein hormone secreted by the pituitary gland that consists of two different subunits: the α subunit and the β subunit. The human FSH β subunit consists of 111 amino acids and has a specific biological role, responsible for interacting with the FSH receptor (FSHR) located on the surface of target cells, usually the testis and ovary (granulosa cells and Sertoli cells) [1]. Therefore, FSH plays a key role in the reproductive process, stimulating the formation of the antral secondary follicles in females and the growth and maturation of antral follicles, while FSH in males is responsible for the development and maintenance of the testes. In the mature gonads, FSH acts on Sertoli cells, spermatogonia, primary and secondary spermatocytes, and drives spermatogenesis [2].
[0003] The expression of FSH receptor (FSHR) is not limited to the gonads. Recent studies have found that FSHR is also expressed in adipose tissue and liver outside the gonads, suggesting that FSH may play a role in regulating lipid metabolism and fat accumulation [3]. Further studies have shown that FSH plays an important role in promoting fat accumulation in both women and men. In particular, elevated FSH levels in menopausal women due to ovarian failure have been shown to be the main cause of menopausal obesity and hepatic steatosis. Studies using mouse models have also shown that high expression of FSH is the main cause of gonadectomy-induced obesity in mammals.
[0004] In addition to being closely related to obesity, studies have also found that FSH can increase the risk of osteoporosis, atherosclerosis, hypercholesterolemia, prostate cancer and neurodegenerative diseases [4,5].
[0005] These findings provide new perspectives for studying disease control in humans and mammals. The development of an effective FSH vaccine has broad prospects in controlling obesity, osteoporosis and neurodegenerative diseases, especially for menopausal women and some livestock or pets that need to be castrated and then fattened.
[0006] A study reported that a new FSH vaccine was developed based on the FSH receptor binding epitope of the FSHβ subunit. Vaccination with this vaccine is very effective in preventing fat accumulation caused by ovariectomy in mice, and can also effectively prevent fat accumulation in intact mice fed a normal diet [6]. This study designed a new FSH antigen and vaccine by synthesizing a tandem FSHβ13AA (LVYKDPARPNIQK) and combining it with ovalbumin (FSHβ13AA-T-OVA), and used a mouse model to demonstrate its high efficiency in inhibiting fat accumulation. This therapeutic effect is also confirmed in the patent (CN110694056A).
[0007] In addition, earlier studies have shown that FSH has been studied as a candidate for the development of a contraceptive vaccine. Spermatogenesis was inhibited and testicular atrophy occurred in adult rhesus monkeys after vaccination with ovine FSH (oFSH). Other research groups have also independently confirmed that oFSH immunization reduces fertility in Bonnet monkeys and men [7-10].
[0008] The latest research found that recombinant FSHR subunit vaccine can significantly inhibit testicular development and spermatogenesis in prepubertal and pubertal rats
[11] .
[0009] This means that FSH vaccine may have the same mechanism of action as FSHR vaccine and is a promising method for animal immunocastration. Faced with many stray cats and dogs, as well as wild animals that need to be sterilized to control breeding populations, it is obviously unrealistic to sterilize them all surgically. The market still lacks more mature immunocastration products, and the development of FSH vaccine will be beneficial to the sterilization of animals and pets, avoid the pain of surgical castration, and enhance animal welfare, so it has great commercial value. Summary of the invention
[0010] The purpose of the present invention is to provide a vaccine suitable for reducing lipids, blood sugar and castration in multiple species, a preparation method and application thereof, so as to solve the problems raised in the above background technology.
[0011] To solve the above technical problems, the technical solution provided by the present invention is: a vaccine suitable for reducing lipids, blood sugar and castration in multiple species, designed for specific fragments of FSHβ subunits of multiple species, involving the YETVKVPGCAHHADSL fragment of pigs, cattle, sheep, alpacas and horses, the YETVRVPGCARHADSL fragment of dogs and minks, the YPVATECHCGK fragment of pigs, cattle, sheep, alpacas, cats, rabbits and mice, the CDSDSTDCTVRGLGP of humans, pigs, cattle, sheep, alpacas, dogs, giant pandas, rabbits and mice, and the CDSDSTDCTVQGLGP fragments of cats, tigers and lions, or a combination of any one or more of them, and any sequence with a homology of more than 70%.
[0012] Preferably, the above fragments are connected by a rigid linker A (EAAAK) n Connect the sequences.
[0013] As a preferred method, in order to enhance immunogenicity, TEV restriction enzyme sequence ENLYFQSA is added on both sides of the rigid linker sequence to make it compatible with rigid linker A (EAAAK) n After fusion, it has a coiled coil structure that enables the entire antigen to form a stable dimer, adds lytic peptides to enhance cell expression, and fuses antimicrobial peptides at the C-terminus of the antigen to further enhance immunogenicity.
[0014] Methods for preparing multi-species lipid-lowering, blood sugar-lowering, castration-resistant vaccines and their use for topical use in the form of creams, oils, ointments, powders or gels.
[0015] The invention relates to a method for preparing a vaccine for reducing lipids, blood sugar and castration in multiple species and its application, which is administered orally, transdermally, transmucosally, intramuscularly, intravenously or subcutaneously.
[0016] A method for preparing a vaccine for reducing lipids, blood sugar and castration in multiple species, comprising the following steps:
[0017] 1) Synthesize the sequence and construct it into the vector pcDNA3.4;
[0018] 2) Cell passaging before transfection: When culturing cells, the volume of the culture medium should not exceed 1 / 5 of the volume of the shake flask. The cells should be passaged once every 3-4 days. When passing the cells, the cells should be accurately counted first. After confirming the density, the cell suspension should be prepared into Hi-KDCHO culture medium according to the required ratio without centrifugation. The cell density after passage should be controlled at 0.4-0.6×10 6 cells / ml;
[0019] 3) Prepare cells for transfection: Place CHOK1-Hi cells in 5% CO 2 Incubate the cells in a constant temperature shaker at 37°C to determine the cell density and survival rate. 6 cells / ml, calculate and transfer the required volume of cell suspension into a centrifuge tube, centrifuge at 1000 rpm for 5 min, discard the supernatant, and resuspend the cells in fresh Hi-KDCHO culture medium to a density of 20×10 6 cells / ml;
[0020] 4) Transient transfection: transfer the cells to a cell culture shake flask and place it back in the shaker. After shaking and culturing for 1 hour, remove the cells from the shaker for transfection. During transfection, add plasmid DNA to the cells at a concentration of 17 μg / ml and shake well. Then add transfection reagent HiKDCHO-TA at a concentration of 35 μg / ml and mix well.
[0021] 5) Product expression and detection: 24 hours after transfection, add 2% (2ml / 100ml) of CHO cell protein expression enhancer Hi-KEplus; at the same time, add a nutritional supplement additive HiKDCHO-Feed at a rate of 2% (2ml / 100ml), and transfer the cells to a 32°C shaking incubator for low-temperature expression to achieve high expression effects; measure the product expression level on the 6th to 8th day after transfection;
[0022] 6) Protein purification: The protein was purified using a Ni Smart Beads 6FF gravity column (Changzhou Tiandi Renhe Biotechnology Co., Ltd.), and the imidazole was washed away using an ultrafiltration tube. The purity of the obtained protein was ≥95%.
[0023] The advantages of the present invention are that the protein vaccine provided by the present invention can be effectively used to treat obesity, hyperlipidemia, diabetes and other diseases caused by ovarian dysfunction, and is expected to become a new, effective, defensive and therapeutic drug, which has the effect of sterilizing pets and animals, and can treat postmenopausal women or animals and pets that have undergone sterilization or castration surgery, as well as obesity, hyperlipidemia, hyperglycemia and other diseases caused by ovarian dysfunction. The new protein vaccine has good promotion prospects and medical and economic value. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 It is a bar graph showing the effect of ZD9A on intraluminal fat.
[0025] Figure 2 It is a bar graph showing the effect of ZD9A on triglycerides.
[0026] Figure 3 It is a line graph showing the effect of vaccination on body weight.
[0027] Figure 4 It is a line graph showing the effect of vaccine on blood sugar after immunization.
[0028] Figure 5 It is a line graph showing the effect of vaccination on total cholesterol.
[0029] Figure 6 The effect of vaccination on triglycerides Figure 1 .
[0030] Figure 7 The effect of vaccination on triglycerides Figure 2 .
[0031] Figure 8 It is a line graph showing the effect of vaccine on high-density lipoprotein after immunization.
[0032] Fig. 9This is a photo of the effect of vaccine immunization on castrated mice.
[0033] Fig.10 This is a photo of the ovaries of normal mice 11 weeks after immunization. DETAILED DESCRIPTION
[0034] For the purpose of the following detailed description, it should be understood that the present invention may adopt various alternative changes and step sequences, unless expressly specified to the contrary. In addition, except in any operating examples, or otherwise indicated, all numbers representing the amount of ingredients used in the specification and claims should be understood to be modified by the term "about" in all cases. Therefore, unless otherwise indicated, the numerical parameters set forth in the following specification and the attached claims are approximate values that vary according to the desired performance to be obtained by the present invention. At least it is not intended to limit the application of the doctrine of equivalents to the scope of the claims, and each numerical parameter should at least be interpreted according to the number of reported significant figures and by applying ordinary rounding techniques.
[0035] Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements.
[0036] In addition, it should be understood that any numerical range described herein is intended to include all subranges subsumed therein. For example, a range of "1 to 10" is intended to include all subranges between (and including) the stated minimum value of 1 and the stated maximum value of 10, i.e., having a minimum value equal to or greater than 1 and a maximum value equal to or less than 10.
[0037] Example
[0038] A vaccine suitable for lowering blood lipids and blood sugar and castration in multiple species, designed for specific fragments of FSHβ subunits of multiple species, involving the YETVKVPGCAHHADSL fragment of pigs, cattle, sheep, alpacas, and horses, the YETVRVPGCARHADSL fragment of dogs and minks, the YPVATECHCGK fragment of pigs, cattle, sheep, alpacas, cats, rabbits, and mice, the CDSDSTDCTVRGLGP of humans, pigs, cattle, sheep, alpacas, dogs, giant pandas, rabbits, and mice, and the CDSDSTDCTVQGLGP fragments of cats, tigers, and lions, or a combination of any one or more of these fragments, and any sequence with a homology of more than 70%.
[0039] As a preferred implementation of this embodiment, the above fragments are connected by a rigid joint A (EAAAK) n Connect the sequences.
[0040] As a preferred implementation of this embodiment, in order to enhance immunogenicity, TEV restriction enzyme sequence ENLYFQSA is added on both sides of the rigid linker sequence to make it compatible with the rigid linker A (EAAAK) n After fusion, it has a coiled coil structure that enables the entire antigen to form a stable dimer, adds lytic peptides to enhance cell expression, and fuses antimicrobial peptides at the C-terminus of the antigen to further enhance immunogenicity.
[0041] Methods for preparing multi-species lipid-lowering, blood sugar-lowering, castration-resistant vaccines and their use for topical use in the form of creams, oils, ointments, powders or gels.
[0042] The invention relates to a method for preparing a vaccine for reducing lipids, blood sugar and castration in multiple species and its application, which is administered orally, transdermally, transmucosally, intramuscularly, intravenously or subcutaneously.
[0043] A method for preparing a vaccine for reducing lipids, blood sugar and castration in multiple species, comprising the following steps:
[0044] 1) The following sequences were synthesized and constructed into the plasmid vector pcDNA3.4;
[0045] YETVKVPGCAHHADSLYETVKVPGCAHHADSLYETVRVPGCARHADSLYETVRVPGCARHADSL ENLYF QS AEAAAKE
[0046] AAAKEAAAKEAAAKALEAEAAAKEAAAKEAAAKAAAKEA ENLYFQS AVQHSNAPLIDLGAEMKKQHKEAAPEGAAP
[0047] AQGKAPAAEAKKEEAPKPKPVV ENLYFQSA YPVATECHCGKCDSDSTDCTVRGLGPCDSDSTDCTVQGLGPCDSDSTD
[0048] CTVRGLGPCDSDSTDCTVRGLGPCDSDSTDCTVRGLGP QCRRLCYKQRCVTYCRGR
[0049] 2) Cell passaging before transfection: When culturing cells, the volume of the culture medium should not exceed 1 / 5 of the volume of the shake flask. The cells should be passaged once every 3-4 days. When passing the cells, the cells should be accurately counted first. After confirming the density, the cell suspension should be prepared into Hi-KDCHO culture medium according to the required ratio without centrifugation. The cell density after passage should be controlled at 0.4-0.6×10 6 cells / ml;
[0050] 3) Prepare cells for transfection: Place CHOK1-Hi cells in 5% CO 2 Incubate the cells in a constant temperature shaker at 37°C to determine the cell density and survival rate. 6 cells / ml, calculate and transfer the required volume of cell suspension into a centrifuge tube, centrifuge at 1000 rpm for 5 min, discard the supernatant, and resuspend the cells in fresh Hi-KDCHO culture medium to a density of 20×10 6 cells / ml;
[0051] 4) Transient transfection: transfer the cells to a cell culture shake flask and place it back in the shaker. After shaking and culturing for 1 hour, remove the cells from the shaker for transfection. During transfection, add plasmid DNA to the cells at a concentration of 17 μg / ml and shake well. Then add transfection reagent HiKDCHO-TA at a concentration of 35 μg / ml while mixing.
[0052] 5) Product expression and detection: 24 hours after transfection, add 2% (2ml / 100ml) of CHO cell protein expression enhancer Hi-KEplus; at the same time, add a nutritional supplement additive HiKDCHO-Feed at a rate of 2% (2ml / 100ml), and transfer the cells to a 32°C shaking incubator for low-temperature expression to achieve high expression effects; measure the product expression level on the 6th to 8th day after transfection;
[0053] 6) Protein purification: The protein was purified using a Ni Smart Beads 6FF gravity column (Changzhou Tiandi Renhe Biotechnology Co., Ltd.), and the imidazole was washed away using an ultrafiltration tube. The purity of the obtained protein was ≥95%.
[0054] The present invention uses case 1 as follows:
[0055] Mice were immunized with 20 micrograms of vaccine as the castration medication group (ZD9A). The castration group (Castration) and the control group (Control) were injected with an equal volume of normal saline as a placebo, intramuscularly once every 21 days, for 3 consecutive injections. After another 2 weeks, the abdominal fat and blood lipids were tested. The results showed that compared with the castration group, after the injection of FSH vaccine, the abdominal fat decreased by 68% ( Figure 1 and Fig. 9 ), triglycerides decreased by 15% ( Figure 2 )
[0056] The present invention uses case 2 as follows:
[0057] Diabetic rats were immunized with 60 μg of vaccine as the immunized group (ZD9A), and the control group (Control) was injected with an equal volume of saline as a placebo.
[0058] The results show:
[0059] Weight: The weight of the ZD9A group increased in weeks 1 and 2, but remained stable in weeks 3 and 5. The weight of the control group continued to increase. ZD9A may help control weight gain ( Figure 3 ).
[0060] Blood sugar: The blood sugar level in the ZD9A group increased in the first week, but gradually decreased in the second, third, fourth and fifth weeks, indicating that ZD9A significantly reduced blood sugar levels. The blood sugar level in the control group peaked in the second week and then decreased slightly ( Figure 4 ).
[0061] TC: TC levels in the ZD9A group increased in the first week, but gradually decreased in the second and third weeks, indicating that ZD9A may help control TC levels. TC levels in the control group continued to increase ( Figure 5 ).
[0062] TG: The TG level in the ZD9A group gradually decreased in the first, second, and third weeks, indicating that ZD9A may help to reduce TG levels. The TG level in the control group remained stable after decreasing in the first week ( Figure 6 ).
[0063] HDL: HDL levels in the ZD9A group decreased in the first week, but gradually increased in the second and third weeks. HDL levels in the control group continued to increase. ZD9A did not limit the increase in HDL ( Figure 7 ).
[0064] LDL: LDL levels increased in the ZD9A group after the first week, but gradually decreased in the second and third weeks, indicating that ZD9A may help lower LDL levels. The control group had an overall increase in LDL levels ( Figure 8 ).
[0065] As can be seen above, the vaccine of the present invention shows significant effects in reducing LDL, TG and blood sugar levels, and may help control total cholesterol and body weight. Overall, the vaccine of the present invention shows potential therapeutic effects in diabetic rat models, especially in reducing blood sugar and blood lipids.
[0066] The vaccine of the present invention has the effect of sterilizing animals. As an example, 8-week-old ICR female mice were used and injected once every 21 days. After 3 consecutive injections, ovulation induction was used 2 weeks later. 10 IU of pituitary follicle-stimulating hormone (Ningbo Second Hormone Factory) was injected every day for 3 consecutive days. On the 3rd day, 5 IU of chorionic gonadotropin (Ningbo Second Hormone Factory) was injected once. On the 4th day, ovulation was observed. The results showed that the mouse ovaries did not ovulate, and no obvious development of follicles was observed in the ovaries. Fig.10 The results show that the present invention can be used as a castration vaccine for sterilization of animals.
[0067] The present invention relates to vaccine sequences
[0068] YETVKVPGCAHHADSLYETVKVPGCAHHADSLYETVRVPGCARHADSLYETVRVPGCARHADSL ENLYF QS AEAAAKEAAAK
[0069] EAAAKEAAAKALEAEAAAKEAAAKEAAAKAAAKEA ENLYFQS AVQHSNAPLIDLGAEMKKQHKEAAPEGAAPAQGKAPAA
[0070] EAKKEEAPKPKPVV ENLYFQSA YPVATECHCGKCDSDSTDCTVRGLGPCDSDSTDCTVQGLGPCDSDSTDCTVRGLGPCDSD
[0071] STDCTVRGLGPCDSDSTDCTVRGLGP QCRRLCYKQRCVTYCRGR
[0072] The above description is only a preferred specific implementation manner of the present invention, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can make equivalent replacements or changes according to the technical scheme and inventive concept of the present invention within the technical scope disclosed by the present invention, which should be covered by the protection scope of the present invention.
[0073] 1.Bhartiya,D.and H.Patel,An overview of FSH-FSHR biology and explaining the existing conundrums.J Ovarian Res,2021.14(1):p.144.
[0074] 2.Rannikko,A.,et al.,Stage-specific expression of the FSH receptorgene in the prepubertal and adult rat seminiferous epithelium.J Endocrinol,1996.151(1):p.29-35.
[0075] 3.Cui,H.,et al.,FSH stimulates lipid biosynthesis in chicken adiposetissue by upregulating the expression of its receptor FSHR.J Lipid Res,2012.53(5):p.909-917.
[0076] 4.Spaziani,M.,et al.,Extra-Gonadal and Non-Canonical Effects of FSHin Males.Pharmaceuticals(Basel),2023.16(6).
[0078] 5.Frolinger,T.,et al.,Gene-Dose-Dependent Reduction Fshr ExpressionImproves Spatial Memory Deficits in Alzheimer's Mice.Res Sq,2024.
[0079] 6.Han,X.,et al.,A novel follicle-stimulating hormone vaccine forcontrolling fat accumulation.Theriogenology,2020.148:p.103-111.
[0081] 7.Wickings,E.J.and E.Nieschlag,Suppression of spermatogenesis overtwo years in rhesus monkeys actively immunized with follicle-stimulatinghormone.Fertil Steril,1980.34(3):p.269-74.
[0082] 8.Moudgal,N.R.,et al.,Long-term contraceptive efficacy of vaccine ofovine follicle-stimulating hormone in male bonnet monkeys(Macaca radiata).JReprod Fertil,1992.96(1):p.91-102.
[0083] 9.Moudgal,N.R.,et al.,Responsiveness of human male volunteers toimmunization with ovine follicle stimulating hormone vaccine:results of apilot study.Hum Reprod,1997.12(3):p.457-63.
[0084] 10.Srivastav,A.and R.P.Das,Sperm production and fertility of bonnetmonkeys(Macaca radiata)following immunization with ovine follicle stimulatinghormone.Indian J Exp Biol,1992.30(7):p.574-7.
[0085] 11.Pan,F.,et al.,Effects of Vaccination against Recombinant FSH or LHReceptor Subunits on Gonadal Development and Functioning Male Rats.Vet Sci,2024.11(4).
Claims
1. A vaccine for reducing lipids, blood sugar and castration applicable to multiple species, characterized by: Specific fragments of FSHβ subunits of multiple species are designed, including the YETVKVPGCAHHADSL fragment of pigs, cattle, sheep, alpacas, and horses, the YETVRVPGCARHADSL fragment of dogs and minks, the YPVATECHCGK fragment of pigs, cattle, sheep, alpacas, cats, rabbits, and mice, the CDSDSTDCTVRGLGP fragment of humans, pigs, cattle, sheep, alpacas, dogs, giant pandas, rabbits, and mice, and the CDSDSTDCTVQGLGP fragment of cats, tigers, and lions, or a combination of any sequence with a homology of more than 70%.
2. A vaccine for reducing lipids, blood sugar and castration applicable to multiple species as described in claim 1, characterized in that: The above fragments are connected by a rigid linker A (EAAAK) n Connect the sequences.
3. A vaccine for reducing lipids, blood sugar and castration applicable to multiple species as described in claim 2, characterized in that: To enhance immunogenicity, TEV restriction enzyme sequences ENLYFQSA were added to both sides of the rigid linker sequence to make it compatible with the rigid linker A (EAAAK). n After fusion, it has a coiled coil structure that enables the entire antigen to form a stable dimer, adds lytic peptides to enhance cell expression, and fuses antimicrobial peptides at the C-terminus of the antigen to further enhance immunogenicity.
4. Use of a vaccine suitable for reducing lipids, blood sugar and castration in multiple species according to any one of claims 1 to 3, characterized in that: For topical use in the form of cream, oil, ointment, powder or gel.
5. Use of a vaccine suitable for reducing lipids, blood sugar and castration in multiple species according to any one of claims 1 to 3, characterized in that: Administration is by oral, transdermal, transmucosal, intramuscular, intravenous or subcutaneous route.
6. A method for preparing a vaccine suitable for reducing lipids, blood sugar and castration in multiple species, characterized in that: The CHO cell expression system was used, but other protein expression systems are not limited to this expression system.
Citation Information
Patent Citations
FSH antigen, preparation method thereof and FSH vaccine containing antigen
CN110694056A
FSHR-DTT recombinant castration vaccine as well as preparation method and application thereof
CN116063576A
FSH Formulation
US20030166525A1
Novel peptides useful in enhancement of FSH action
WO1997012038A1
